Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Scleroderma (Systemic Sclerosis) | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2019
Systemic sclerosis (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that manifests as Raynaud’s disease and, often, painful…
Graft-Versus-Host Disease | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2019
GVHD is a potentially life-threatening complication of allogenic HCST. GVHD is a systemic inflammatory reaction triggered by donor T cells’ recognition of host cell antigens in nontarget tissue…
Malignant Melanoma | Unmet Need | BRAF-mutation-positive Unresectable or Metastatic | US/EU | 2019
Treatment of BRAF-mutation-positive unresectable or metastatic malignant melanoma has been transformed by the development of several combination regimens that include BRAF and MEK inhibitors, as…
Immune Checkpoint Inhibitors – Access & Reimbursement – Access & Reimbursement – Immune Checkpoint Inhibitors in Bladder Cancer, NSCLC, and Malignant Melanoma (US)
Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications, including non-small-cell lung cancer (NSCLC), malignant melanoma, and bladder cancer. As premium-…
Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Detailed, Expanded Analysis: Special Focus on Retinal Therapies: US Payer Management of the Medical Benefit
As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to impose…
Special Focus on Retinal Therapies: Payer Management of the Medical Benefit | Access & Reimbursement | US | 2019
As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to impose…
Amyotrophic Lateral Sclerosis | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2019
Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron disorder that leads to progressive muscle wasting and weakness. The typical survival time is three to five years from onset. The…
